Table of Contents:
  • Contents: Food allergy
  • Rates of food-induced anaphylaxis are increasing
  • Oral Immunotherapy (OIT)
  • IMPACT Study
  • POISED phase 2 study
  • Anti-IgE antibody
  • Omalizumab facilitates OIT build-up speed
  • MAP-X: phase 2 multifood allergen trial with Xolair
  • MIMIX Study
  • Omalizumab meta-analysis
  • Comparing ligelizumab and omalizumab
  • Patient management of food allergy